Blockade of CCR5+ T Cell Accumulation in the Tumor Microenvironment Optimizes Anti‐TGF‐β/PD‐L1 Bispecific Antibody

Blockade of CCR5+ T Cell Accumulation in the Tumor Microenvironment Optimizes Anti‐TGF‐β/PD‐L1 Bispecific Antibody

Abstract In the previous studies, anti‐TGF‐β/PD‐L1 bispecific antibody YM101 is demonstrated, with superior efficacy to anti‐PD‐L1 monotherapy in multiple tumor models. However, YM101 therapy can not achieve complete regression in most tumor‐bearing mice, suggesting the presence of other immunosuppr...

Full description

Saved in:
Bibliographic Details
Main Authors: Ming Yi, Tianye Li, Mengke Niu, Yuze Wu, Bin Zhao, Zhuoyang Shen, Shengtao Hu, Chaomei Zhang, Xiaojun Zhang, Jing Zhang, Yongxiang Yan, Pengfei Zhou, Qian Chu, Zhijun Dai, Kongming Wu
Format: Article
Language:English
Published: Wiley 2024-11-01
Series:Advanced Science
Subjects:
bispecific antibody
CCR5
cancer immunotherapy
combination therapy
tumor microenvironment
TGF‐β, PD‐L1
Online Access:https://doi.org/10.1002/advs.202408598
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/advs.202408598

Similar Items